Tech Guru
Long/short equity, biotech, healthcare, tech

IntelliPharmaCeutics Sell Off On Acura Data Overdone... Compelling Entry Point

IntelliPharmaCeutics' (NASDAQ:IPCI) shares were weak (-5%) on the heels of disappointing data from Acura Pharmaceuticals (NASDAQ:ACUR) [which was down -20% on the news] for a product ostensibly similar to its Rexista technology. The stock could potentially decline some more as investors digest the news over the next few days, which I believe could be a compelling buying opportunity. The stock has been thinly covered on this Board, and the latest action may prompt some to revisit the story.

First, Some Brief Background

IntelliPharmaCeutics International Inc. (IPCI) is a pharmaceutical company specializing in the research, development and manufacture of generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technologies are a multidimensional controlled-release...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details